Oruka Therapeutics (NASDAQ:ORKA) Posts Earnings Results, Misses Estimates By $0.03 EPS

Oruka Therapeutics (NASDAQ:ORKA) posted its quarterly earnings results on Monday. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03), FiscalAI reports.

Oruka Therapeutics Price Performance

Shares of ORKA stock traded up $1.70 during midday trading on Monday, reaching $104.56. 1,598,897 shares of the company traded hands, compared to its average volume of 1,078,571. The firm’s 50 day simple moving average is $88.22 and its two-hundred day simple moving average is $70.57. Oruka Therapeutics has a 1-year low of $25.23 and a 1-year high of $115.51. The firm has a market cap of $6.92 billion, a PE ratio of -51.51 and a beta of -0.34.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ORKA shares. BTIG Research restated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Monday, October 19th. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Mizuho set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, September 3rd. Piper Sandler reissued an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Finally, Wedbush restated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Insider Buying and Selling

In related news, SVP Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock in a transaction on Monday, October 12th. The stock was sold at an average price of $80.60, for a total transaction of $805,919.40. Following the completion of the transaction, the senior vice president directly owned 14,219 shares of the company’s stock, valued at approximately $1,146,051.40. The trade was a 41.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total value of $523,670.00. Following the sale, the insider owned 31,771 shares in the company, valued at approximately $2,376,788.51. The trade was a 18.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 179,950 shares of company stock worth $16,492,680 in the last quarter. Company insiders own 23.49% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments.

The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Oruka was established around antibody programs developed by Paragon Therapeutics and became a publicly traded company in 2024 through a business combination with ARCA biopharma.